Summary of Teleflex Conference Call Company Overview - **Company**: Teleflex - **Industry**: Healthcare, specifically Medical Supplies and Devices Key Points Company Separation and Strategic Focus - Teleflex is separating into two entities: RemainCo and Nuco, due to differing growth profiles and capital allocation strategies [2][4] - The separation was announced in Q4 earnings call in February, with significant inbound interest in the assets [2][3] - The company is prioritizing a sale of Nuco over a spin-off, with advanced stages of due diligence already in progress [4][5] Performance and Growth - RemainCo is expected to simplify operations, reducing from seven business units and 19 manufacturing sites to three business units and seven manufacturing sites [6] - Excluding volume-based procurement impacts and BIOTRONIK, RemainCo's business is growing at approximately 5% year-to-date [8] - BIOTRONIK, acquired four months ago, reported a growth of approximately 7% in its first year under Teleflex [8][10] BIOTRONIK Integration - BIOTRONIK's focus on complex PCI (Percutaneous Coronary Intervention) complements Teleflex's existing vascular and emergency medicine products [9][10] - The combined sales force will enhance market presence in Europe, Asia, and the U.S., targeting complex PCI procedures [10] - The introduction of Freesolv, a drug-eluting scaffold that absorbs in 12 months, is expected to provide innovative treatment options [12][14] Financial Outlook and Capital Allocation - RemainCo is projected to have better gross margins than Teleflex, with similar operating margins due to increased R&D investments [22][30] - The company plans to balance capital allocation between debt repayment and shareholder returns through share repurchases [29][30] - Tariff impacts have been mitigated from an initial $55 million to approximately $25-$26 million, with ongoing efforts to increase USMCA compliance [24][25] Market Dynamics and Future Considerations - The market for medical devices is expected to grow due to increased diagnosis and prevalence of conditions, with products being used in combination [18][19] - The balloon pump business, initially projected to grow, has faced a slowdown, but Teleflex has gained market share from 30% to 40-45% in the U.S. [33][36] - Future growth strategies will focus on internal R&D and potential smaller acquisitions, depending on market conditions [30][31] Risks and Challenges - The company faces pricing pressures from volume-based procurement in China, although most of its portfolio has already been affected [26][28] - The impact of tariffs and market dynamics will continue to be monitored, with guidance expected in February [25][29] Conclusion Teleflex is strategically positioning itself for growth through the separation of its business units, focusing on enhancing its product portfolio and market presence, particularly with the integration of BIOTRONIK. The company is committed to maximizing shareholder value while navigating market challenges and opportunities.

Financial Data and Key Metrics Changes - The company reported an operating net income of $127 million, or $1.21 per diluted common share, resulting in an annualized operating return on average equity (ROAE) of 21.4%, an increase of five points year over year [11][12] - The combined ratio for the quarter was 79%, the best as a publicly traded company, and an improvement of more than eight points from the same quarter last year [4][13] - The diluted book value per share grew by $1.25 in the quarter, reaching $23.29, which is an increase of 8.3% since year-end [11][12] Business Line Data and Key Metrics Changes - Gross premiums written increased by 8% to $798 million for the quarter, with year-to-date gross premiums written at $3.7 billion, also an increase of 8% compared to the same period last year [11][12] - In the insurance segment, gross premiums written grew by 4% to $606 million, while the reinsurance segment saw gross premiums written increase to $192 million from $159 million in the prior year period, driven by new business opportunities [11][12] - The direct property book grew by 9.5% year on year, supported by new opportunities at compelling pricing [6][12] Market Data and Key Metrics Changes - The company experienced strong performance in the property and asset-backed finance sectors, with overall RPI remaining broadly flat, reflecting the differentiated position and product diversification [6][7] - The reinsurance segment delivered 20% year-on-year premium growth, driven by enhanced pricing at 7.1, particularly benefiting from post-wildfire opportunities [9][12] Company Strategy and Development Direction - The company is focused on driving profitable growth through strategic capital allocation and expert risk selection, balancing profitable growth with returning capital to shareholders [5][17] - The ongoing expansion of underwriting partnerships is a strategic priority, with the total number of underwriting partners growing to the mid-single digits [19][20] - The company aims to maintain a disciplined approach to underwriting, even as competition increases in certain lines, ensuring attractive margins and risk-reward dynamics [22][24] Management's Comments on Operating Environment and Future Outlook - Management remains bullish about the market, indicating that the company is in a prevailing hard market with opportunities for growth [29][30] - The company is cautious in the aviation sector, which remains highly competitive, while expressing confidence in the marine sector due to stable pricing and new business opportunities [64][68] - Management emphasized the importance of maintaining underwriting discipline and leveraging strong relationships with brokers and clients to capitalize on market opportunities [70][72] Other Important Information - The company repurchased 1.8 million common shares for $32 million at an average price of $17.40 per share during the quarter, with additional repurchases following [17][18] - The effective tax rate for the first nine months of the year was 18.8%, reflecting a greater proportion of pre-tax income generated in higher tax rate jurisdictions [16] Q&A Session Summary Question: Thoughts on reinsurance growth and expectations for 2026 - Management remains optimistic about the market, indicating that they expect to continue seeing growth opportunities across their portfolio, particularly through new underwriting partners [29][30] Question: Stability of RPIs and competitive pressures - Management acknowledged that while there is pressure in certain lines, they are able to maintain strong retention rates and margins, leveraging their leadership position [32][33] Question: Exposure to Caribbean hurricane losses - Management indicated that while there is some exposure, it is too early to provide detailed numbers, but they expect any net losses to fall within their expected cap load [51] Question: Partnerships and capabilities in data center construction - Management highlighted their ability to deploy meaningful line sizes through their partnership structure, allowing them to negotiate favorable terms and conditions [52][53] Question: Valuation concerns and market multiples - Management agreed that they believe the company is undervalued relative to peers and emphasized the importance of consistent strong underwriting results to unlock value [46][47]

Core Insights - Manulife Financial's core earnings reached a record high of CAD 2 billion for the third quarter ending September 30, 2025, representing a 10% increase compared to the same period in 2024 when adjusted for constant currency [1] - The core EPS increased by 16% to CAD 1.16, while the overall EPS rose by 2% to CAD 1.02 [1] - The company reported a core ROE of 18.1%, up from 16.0% in the previous year [1] Financial Performance - The net income attributable to shareholders was CAD 1.8 billion, remaining stable compared to the third quarter of 2024 [1] - The APE sales increased by 8% year-over-year, while the new business CSM grew by 25% and the new business value increased by 11% [1] - The LICAT ratio stood at 138%, indicating strong capital adequacy [1] Business Operations - Despite experiencing net outflows of CAD 6.2 billion in global wealth and asset management, the core EBITDA margin continued to expand, demonstrating effective operational leverage [2] - The company successfully acquired Comvest Credit Partners and reached an agreement to acquire Schroders' Indonesian business, enhancing service capabilities and client offerings [2] - The updated strategy aims to strengthen confidence in achieving the 2027 targets and solidify Manulife's position as a leading diversified financial services firm headquartered in Canada [2]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $341.1 million, slightly up from $340.4 million in Q2 2025, and about 4% higher than expectations [32] - Gross margin for Q3 was 48%, exceeding guidance by 200 basis points but down from 50% in Q2 [4][33] - Free cash flow generated in Q3 was $83 million, bringing total free cash flow for the first nine months of 2025 to nearly $275 million [5] - Net loss for the quarter was $806,000, or $0.02 per share, impacted by a $27.1 million charge related to early debt extinguishment [32][39] Business Line Data and Key Metrics Changes - Average day rates in Q3 were $22,798, a 2% decrease from Q2 [32] - Active utilization increased from 76.4% in Q2 to 78.5% in Q3, attributed to fewer idle and dry dock days [33] - Revenue increased in the APAC, Middle East, and Americas regions, while Europe, the Mediterranean, and Africa saw declines [35] Market Data and Key Metrics Changes - The offshore vessel market is expected to see a recovery in drilling activity towards the end of 2026, with increasing demand for production support and EPCI projects [9][10] - The OSCE order book remains limited, with only 134 units representing about 3% of the current fleet, indicating moderate supply growth [24] - Day rates in the Middle East strengthened, while Europe faced pressure, particularly in the U.K. [25][28] Company Strategy and Development Direction - The company is focused on capital allocation, with a $500 million share repurchase authorization in place, but did not repurchase shares in the last quarter due to competing priorities [6][15] - The company is optimistic about long-term growth in the offshore vessel industry and is well-positioned to drive earnings and free cash flow [14][42] - M&A opportunities are being explored, with a preference for large PSVs and medium to large anchor handlers [79] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the recovery of drilling activity and the overall positive long-term outlook for the offshore space [23][30] - There is an expectation of a gradual increase in drilling demand, supported by a robust EPCI backlog [10][24] - Management noted that while short-term headwinds exist, the fundamentals of the business remain strong [30] Other Important Information - The company successfully refinanced its debt, resulting in a more favorable debt structure with no payments due until 2030 [39] - Dry dock costs for 2025 are projected to be $105 million, slightly down from previous estimates [40] - Capital expenditures for 2025 are projected at $30 million, down $7 million from prior forecasts [41] Q&A Session Summary Question: Market shaping for 2026 and pricing leverage - Management expects production support and EPCI activity to grow, which may lead to pricing recovery sooner than previously anticipated [45][46] Question: Capital allocation and M&A opportunities - Management acknowledged having material non-public information during the quarter, indicating potential M&A discussions [48] Question: Guidance for 2026 and regional exposure - Management provided guidance for 2026, indicating confidence in performance and noted that Africa and Asia have more exposure to open capacity [52][56] Question: Confidence in customer plans and offshore activity - Management noted that customers appear more confident in their plans, with increased tender activity expected [64][68] Question: Contract durations and market conditions - Contracts signed were primarily to maintain utilization while avoiding overcommitment, anticipating market uplift in late 2026 [70][71] Question: New build fleet and attrition expectations - Management discussed the limited new build activity and expected attrition, suggesting a balanced supply outlook [74][76]

Teva Pharmaceutical Industries Conference Summary Company Overview - **Company**: Teva Pharmaceutical Industries (NYSE: TEVA) - **Event**: UBS Global Healthcare Conference - **Date**: November 10, 2025 Key Highlights Industry and Company Strategy - Teva has implemented a "pivot to growth" strategy over the past three years, focusing on three phases: return to growth, accelerate growth, and maintain growth [3][4] - The company has achieved its 11th consecutive quarter of growth in Q3 2025, marking a significant turnaround after years of decline [3][4] Financial Performance - Innovative business sales exceeded $800 million in Q3 2025, representing a 33% increase year-over-year [4] - Specific product growth rates in Q3 2025: - Austedo: up 38% - Ajovy: up 19% - UZEDY: up 24% [4] - Gross margin improved from 48% in Q1 2023 to a projected range of 40%-55% due to efficiency drives and a shift in product portfolio [4][5] Product Development and Pipeline - Teva is transitioning from a generics-focused company to a biopharma company with a strong innovative portfolio [6] - Upcoming product launches include: - Olanzapine (expected launch in the second half of 2026) [38] - Duvakitug (phase three trials for ulcerative colitis and Crohn's disease) [39] - DARI (dual action rescue inhaler) with a planned market entry in 2027 [43] Market Dynamics and Competitive Landscape - Teva is focusing on increasing patient access to its products, particularly in the Austedo market, where 85% of patients are untreated [11][12] - The company is cautious about pricing strategies, maintaining discipline to avoid discounting unless necessary [30] - Teva is preparing for a more challenging payer market, emphasizing the importance of balancing value and access [12][13] Long-term Financial Guidance - Teva reiterated its 2027 revenue guidance of $2.5 billion to $3 billion for Austedo and $1.5 billion to $2 billion for its schizophrenia franchise [32][55] - The company aims for mid-single-digit compound annual growth rate (CAGR) in revenue despite the anticipated loss of Revlimid in 2026 [55] Capital Allocation and Strategic Decisions - Teva is reassessing its non-core assets, including the TAPI API business, to ensure alignment with its long-term biopharma strategy [57][58] - The company is committed to thoughtful capital allocation, focusing on investments that drive long-term value [19][61] Biosimilars and Generics - Teva is expanding its biosimilars portfolio through partnerships, aiming for over 30 biosimilars in the market [46] - The company views recent FDA simplifications in clinical trial requirements positively, believing it will not lead to a significant influx of competitors due to the high technical and financial barriers [45][46] Additional Insights - Teva's OTC business is seen as synergistic with its generics and innovative products, contributing to overall growth [60][61] - The company emphasizes the importance of understanding the patient journey and optimizing treatment pathways to enhance product uptake [9][36] This summary encapsulates the key points discussed during the conference, highlighting Teva's strategic direction, financial performance, product pipeline, and market positioning.

Company Performance & Strategy - Granite Ridge aims to be the leading public investment platform for energy development in the United States, targeting 25% full-cycle returns and mid-teens annual growth[7] - The company's Q3 2025 production reached 31,925 Boe/d, with 51% oil and 49% gas[3] - Granite Ridge has achieved a 47% CAGR growth since 2017 while maintaining leverage below 10x Net Debt/Adjusted EBITDAX[31] - The company declared a quarterly dividend of $011 per share[89] Market Trends & Opportunities - The U S rig count is down approximately 30% since its peak, indicating industry under-investment in new supply[8, 9] - US Frac Spread Count is down approximately 45% compared to pre-COVID levels, potentially impairing future production growth[10, 11] - US shale productivity has peaked, requiring more capital for less output due to depleted Tier 1 inventory[17] - Private equity fundraising in US natural resources has declined by approximately 70%, creating an opportunity for Granite Ridge[40, 41] Capital Allocation & Investment - Granite Ridge has invested over $18 billion in the past 10 years, navigating multiple downturns[35] - The company expects to close over 50 deals in 2025, expanding inventory by over 74 net locations[73] - Non-Op investments account for 35% of the company's 2025 estimated capital allocation, while Operated Partnerships represent 65%[81]

Financial Data and Key Metrics Changes - The company reported sales of $869 million, representing a 9% year-over-year increase, with 6% organic growth [5][6] - Operating income increased by 14% year-over-year, leading to a 90 basis points expansion in overall operating margin to 19.6% [6][14] - Diluted earnings per share (EPS) rose by 14% year-over-year, slightly exceeding expectations [6][9] - Free cash flow was $176 million, up 8% year-over-year, reflecting nearly 140% conversion due to higher cash earnings and lower tax payments [6][9] Business Line Data and Key Metrics Changes - In the aerospace and industrial segment, sales increased by 8%, driven by strong demand in commercial aerospace and ground defense markets [10][11] - The defense electronics segment saw a 4% sales growth, primarily due to tactical communications equipment revenues [11][12] - The naval and power segment experienced a 12% increase in sales, driven by production acceleration on submarine programs [12][13] Market Data and Key Metrics Changes - The order book increased by 8%, resulting in a book-to-bill ratio of 1.1 times, indicating continued confidence in future growth [6][46] - The backlog reached a record of over $3.9 billion, up 14% year-to-date [8][46] - Strong demand for commercial nuclear orders was noted, including new contracts supporting government sites [7][8] Company Strategy and Development Direction - The company is focused on a "pivot to growth" strategy, emphasizing operational excellence and targeted investments [4][24] - There is a strong alignment with U.S. defense priorities, particularly in shipbuilding and defense electronics [25][26] - The company is positioned to capitalize on increased global defense spending and has significant content in key defense programs [25][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning across A&D and commercial markets, anticipating meaningful growth opportunities into the next decade [4][24] - The company raised its full-year 2025 guidance for sales, operating income, and EPS, reflecting strong year-to-date performance [8][9] - Management acknowledged potential impacts from government shutdowns but remained optimistic about the order pipeline and future growth [41][47] Other Important Information - The company plans to maintain a strong focus on research and development while also pursuing strategic acquisitions [33][80] - Increased capital expenditures are anticipated to support future growth initiatives, with a 40% year-over-year increase expected [22][64] Q&A Session Summary Question: Can you provide details on the AP1000 reactor content? - Management confirmed that the content per reactor coolant pump (RCP) is approximately $28 million, with additional content expected to increase significantly [39][40] Question: How are bookings performing across segments? - Overall bookings were strong, with a book-to-bill ratio of 1.1 times, although some delays were noted in the defense electronics segment due to government shutdowns [41][46] Question: What is the outlook for the nuclear market in the U.S.? - Management indicated that the first orders are expected from Poland and Bulgaria, with U.S. orders anticipated to follow, but timing remains uncertain [60][61] Question: What is the capacity for building AP1000 reactors? - The company estimates a capacity of 12-16 reactors per year, with increased capital expenditures aimed at supporting this capacity [62][64] Question: What is the state of the M&A pipeline? - Management confirmed that M&A remains a top priority, with ongoing discussions for strategic acquisitions [80]

Financial Data and Key Metrics Changes - Nutrien reported adjusted EBITDA of $1.4 billion in Q3 2025, a 42% increase compared to the prior year [12] - The company raised its full-year potash sales volume guidance to 14-14.5 million tons, supported by strong offshore demand [14] - Capital expenditures were lowered by 10% year-to-date through optimization efforts [7] Business Line Data and Key Metrics Changes - Upstream fertilizer sales volumes increased by approximately 750,000 tons compared to the same period last year [4] - Potash operations generated adjusted EBITDA of $733 million in Q3 2025, higher than last year due to increased net selling prices [13] - Nitrogen operations achieved a 94% ammonia utilization rate, up 7 percentage points from the previous year [6] - Phosphate operations generated adjusted EBITDA of $122 million in Q3 2025, as higher net selling prices and sales volumes offset increased sulfur costs [15] Market Data and Key Metrics Changes - In North America, a record crop is expected to support the need for replenishing soil nutrients [10] - Global potash shipment projections for 2025 were increased to a record 73-75 million tons, with demand expected to grow at historical trend levels in 2026 [10][11] - Reported port inventories in China are down by more than 1 million tons year over year, indicating strong potash affordability [11] Company Strategy and Development Direction - Nutrien is focused on simplifying its portfolio and reviewing non-core assets, with divestitures expected to generate approximately $900 million in gross proceeds [8] - The company is on track to achieve its $200 million cost reduction target one year ahead of schedule [7] - A strategic review of the phosphate business is underway, evaluating alternatives including reconfiguring operations and potential sales [24] Management's Comments on Operating Environment and Future Outlook - Management expressed a constructive outlook for the business, supported by expectations for healthy crop input demand and growth in global potash shipments in 2026 [18] - The company is assessing options to enhance the long-term financial performance of its Trinidad operations, which were projected to account for approximately 1% of consolidated free cash flow in 2025 [9] - Management highlighted strong execution on strategic priorities and supportive market fundamentals [12] Other Important Information - Nutrien allocated $1.2 billion to dividends and share repurchases in the first nine months, representing a 42% increase from the prior year [7] - The company plans to introduce over 30 new proprietary products globally in 2026, focusing on crop protection and nutritional products [57] Q&A Session Summary Question: Regarding the phosphate business, how does cash generation compare to other segments? - Management noted that phosphate contributes about 6% of EBITDA, prompting a strategic review to maximize free cash flow [23][24] Question: Can you reflect on initiatives undertaken since becoming CFO? - The CFO highlighted significant progress on structural growth initiatives, including a $200 million cost reduction target achieved ahead of schedule [27][30] Question: What is the outlook for the fall season regarding crop nutrient demand? - Management expects nitrogen volumes to be up, potash volumes to be flat, and phosphate volumes to be slightly down compared to last year [37] Question: Can you discuss the Brazilian market environment? - Management confirmed a 2% increase in fertilizer usage in Brazil, with a focus on maximizing yield through appropriate application rates [47][48] Question: What are the possibilities for the Trinidad asset? - The company is exploring optimal operating conditions and assessing options for Trinidad, which contributes less than 1% of free cash flow [80][84]

Financial Data and Key Metrics Changes - Vistra reported $1.581 billion in adjusted EBITDA for Q3 2025, with $1.544 billion from generation and $37 million from retail, reflecting strong performance despite outages [22][23] - The company narrowed its 2025 adjusted EBITDA guidance to $5.7 billion-$5.9 billion and introduced 2026 guidance of $6.8 billion-$7.6 billion [5][6] - The adjusted free cash flow before growth for 2025 is projected at $3.3 billion-$3.5 billion, with 2026 guidance set at $3.925 billion-$4.725 billion [5][6] Business Line Data and Key Metrics Changes - The generation segment benefited from a comprehensive hedging program, achieving average realized prices over $10 per megawatt hour higher than the same quarter last year [22] - The retail business continues to show strong customer count growth and margin performance, expected to outperform 2024 results [10][25] Market Data and Key Metrics Changes - Weather-normalized load in PJM rose approximately 2%-3%, while ERCOT market grew around 6% year-over-year, indicating a structurally improved demand environment [15][16] - Data center development across the U.S. has more than doubled in the past year, with ERCOT's market share of these developments significantly increasing [15][16] Company Strategy and Development Direction - Vistra's strategic priorities include maintaining a disciplined capital allocation approach while targeting significant returns and executing on growth projects [10][11] - The company is advancing its growth efforts with the development of two gas-fired units in West Texas and the acquisition of 2.6 GW of natural gas-fired assets from Lotus Infrastructure Partners [4][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the forecast, citing consistent earnings from the retail business and strong performance from the generation fleet [6][10] - The company highlighted the importance of long-term power purchase agreements and the potential for increased capacity at nuclear plants to meet future electricity needs [14][19] Other Important Information - Vistra has returned over $6.7 billion to shareholders through share repurchases and dividends since implementing its capital return plan [10][26] - The company is targeting approximately $270 million of adjusted EBITDA from the recently acquired assets in 2026, with potential upside from synergies [12] Q&A Session Summary Question: What opportunities are embedded in the 2027 range? - Management indicated that there are several levers to pull, including market exposure and potential contracts that could start in 2027, but specifics are difficult to quantify at this stage [36][38] Question: How are contracting opportunities evolving? - Management noted that all options remain on the table, with record levels of interest across their portfolio and ongoing discussions about various generation types [54][56] Question: Can you provide an update on data center contracting opportunities? - Management stated that the timing of contracts is complex and depends on mutual agreement between parties, but there are possibilities for material deals [88]

Financial Data and Key Metrics Changes - The company reported revenue of $869 million for Q3 2025, representing a 9% year-over-year increase, with 6% organic growth [5] - Operating income increased by 14% year-over-year, leading to an overall operating margin expansion of 90 basis points to 19.6% [5] - Diluted earnings per share (EPS) rose by 14% year-over-year, slightly exceeding expectations due to improved operational performance and fewer shares outstanding [5] - Free cash flow was $176 million, up 8% year-over-year, reflecting nearly 140% conversion due to higher cash earnings and lower tax payments [5] Business Line Data and Key Metrics Changes - In the Aerospace and Industrial segment, sales increased by 8%, driven by strong demand in commercial aerospace and modest growth in aerospace defense [10] - The Defense Electronics segment saw a 4% sales growth, primarily due to tactical communications equipment revenues [11] - The Naval and Power segment experienced a 12% increase in sales, driven by production acceleration on submarine programs [12] Market Data and Key Metrics Changes - The order book increased by 8%, resulting in a book-to-bill ratio of 1.1 times, indicating continued confidence in future top-line growth [5] - The backlog reached a record of over $3.9 billion, up 14% year-to-date [8] - Commercial nuclear orders saw tremendous growth, including new multi-year contracts funded by the DOE [6][8] Company Strategy and Development Direction - The company is focused on a "pivot to growth" strategy, emphasizing operational and commercial excellence while making targeted investments [4] - There is a strong alignment with U.S. defense priorities, particularly in shipbuilding and defense electronics, which are expected to benefit from increased global defense spending [24][25] - The company aims to capitalize on growth opportunities in commercial aerospace and nuclear markets, with expectations for significant revenue growth in the coming years [30][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning across A&D and commercial markets, anticipating meaningful growth opportunities well into the next decade [4] - The company raised its full-year 2025 guidance for sales, operating income, and EPS, reflecting strong year-to-date performance and a growing backlog [8][9] - Management acknowledged potential impacts from the government shutdown but indicated that the overall pipeline remains healthy and growing [37][43] Other Important Information - The company is maintaining its free cash flow guidance while increasing capital expenditures to support future growth initiatives [9][22] - Share repurchase activity has been accelerated, with expectations to exceed $450 million in repurchases for the year [32] Q&A Session Summary Question: Can you provide details on the AP1000 reactor content? - Management confirmed that the content per reactor coolant pump (RCP) is approximately $28 million, with additional content expected to increase significantly [35][36] Question: How did bookings perform by segment, particularly in defense electronics? - The company reported a book-to-bill ratio of 1.1 times, with defense electronics experiencing some order push-outs due to the government shutdown, but the overall pipeline remains strong [37][38] Question: What is the expected timeline for revenue recognition on the AP1000 orders? - Revenue recognition will depend on the timing of material receipts, with some revenue expected in 2026 and a quicker acceleration in 2027 [52][53]